WASHINGTON, D.C.—Severe adverse outcomes of benign prostatic hyperplasia (BPH) persist despite widespread use of oral therapies, according to a study presented at the American Urological Association 2011 annual meeting.
Sean Stroup, MD, of the University of California at San Diego School of Medicine, and colleagues noted in a poster presentation that oral medications have transformed treatment paradigms for BPH. Concomitant trends in hospitalizations for BPH and adverse outcomes of BPH remain undefined, they observed.
The researchers used the Nationwide Inpatient Sample, a 20% sample of United States community hospitals, to characterize inpatient discharges for BPH and adverse outcomes of BPH from 1998 to 2007. The age-adjusted prevalence of BPH among all hospital discharges, regardless of primary diagnosis, increased from 4.2% to 7.4% during the study period. The age-adjusted prevalence of primary BPH decreased from 0.86% to 0.47%. Discharges for BPH surgery decreased 51% and those for primary BPH with acute renal failure increased more than 300%.
In a poster presentation, the investigators concluded stated that increased discharges for primary BPH associated with acute renal failure and stable discharges for other associated conditions indicate that severe adverse outcomes of BPH persist despite widespread use of oral therapies.